DDR-TRK-1 is primarily utilized in the field of cancer research and treatment development. It functions as a potent and selective inhibitor of tropomyosin receptor kinases (TRKs), which are often implicated in various types of cancers due to their role in cell growth and survival signaling pathways. By targeting these kinases, DDR-TRK-1 helps in studying the mechanisms of tumor formation and progression, particularly in cancers driven by TRK fusion proteins. Its application extends to preclinical studies where it aids in evaluating the efficacy of TRK inhibition as a therapeutic strategy. Additionally, DDR-TRK-1 is used in drug development processes to design and optimize new anticancer agents that specifically target TRK pathways, offering potential for personalized medicine approaches in oncology.